Cargando…
Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up
With the Pfizer-BioNTech, Moderna, and now Johnson and Johnson COVID-19 vaccines readily available to the general population, the appearance of vaccine-induced axillary adenopathy on imaging has become more prevalent. We are presenting follow up to the first reported four cases of vaccine induced un...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268700/ https://www.ncbi.nlm.nih.gov/pubmed/34298342 http://dx.doi.org/10.1016/j.clinimag.2021.06.037 |
_version_ | 1783720416098910208 |
---|---|
author | Mehta, Nishi Sales, Rachel Marcus Babagbemi, Kemi Levy, Allison D. McGrath, Anika L. Drotman, Michele Dodelzon, Katerina |
author_facet | Mehta, Nishi Sales, Rachel Marcus Babagbemi, Kemi Levy, Allison D. McGrath, Anika L. Drotman, Michele Dodelzon, Katerina |
author_sort | Mehta, Nishi |
collection | PubMed |
description | With the Pfizer-BioNTech, Moderna, and now Johnson and Johnson COVID-19 vaccines readily available to the general population, the appearance of vaccine-induced axillary adenopathy on imaging has become more prevalent. We are presenting follow up to the first reported four cases of vaccine induced unilateral axillary adenopathy on imaging to our knowledge, which demonstrate expected self-resolving adenopathy. Our hope is that by providing this follow-up and reviewing current management guidelines, clinicians as well as patients will appreciate that this is an expected, benign, and self-resolving finding. In addition, we hope to quell any vaccine hesitancy brought about by recent mainstream media attention to this topic and ultimately empower patients to receive both the COVID-19 vaccine and undergo routine screening mammography, as both are vital to their health. |
format | Online Article Text |
id | pubmed-8268700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82687002021-07-20 Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up Mehta, Nishi Sales, Rachel Marcus Babagbemi, Kemi Levy, Allison D. McGrath, Anika L. Drotman, Michele Dodelzon, Katerina Clin Imaging Breast Imaging With the Pfizer-BioNTech, Moderna, and now Johnson and Johnson COVID-19 vaccines readily available to the general population, the appearance of vaccine-induced axillary adenopathy on imaging has become more prevalent. We are presenting follow up to the first reported four cases of vaccine induced unilateral axillary adenopathy on imaging to our knowledge, which demonstrate expected self-resolving adenopathy. Our hope is that by providing this follow-up and reviewing current management guidelines, clinicians as well as patients will appreciate that this is an expected, benign, and self-resolving finding. In addition, we hope to quell any vaccine hesitancy brought about by recent mainstream media attention to this topic and ultimately empower patients to receive both the COVID-19 vaccine and undergo routine screening mammography, as both are vital to their health. Published by Elsevier Inc. 2021-12 2021-07-09 /pmc/articles/PMC8268700/ /pubmed/34298342 http://dx.doi.org/10.1016/j.clinimag.2021.06.037 Text en © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Breast Imaging Mehta, Nishi Sales, Rachel Marcus Babagbemi, Kemi Levy, Allison D. McGrath, Anika L. Drotman, Michele Dodelzon, Katerina Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up |
title | Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up |
title_full | Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up |
title_fullStr | Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up |
title_full_unstemmed | Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up |
title_short | Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up |
title_sort | unilateral axillary adenopathy in the setting of covid-19 vaccine: follow-up |
topic | Breast Imaging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268700/ https://www.ncbi.nlm.nih.gov/pubmed/34298342 http://dx.doi.org/10.1016/j.clinimag.2021.06.037 |
work_keys_str_mv | AT mehtanishi unilateralaxillaryadenopathyinthesettingofcovid19vaccinefollowup AT salesrachelmarcus unilateralaxillaryadenopathyinthesettingofcovid19vaccinefollowup AT babagbemikemi unilateralaxillaryadenopathyinthesettingofcovid19vaccinefollowup AT levyallisond unilateralaxillaryadenopathyinthesettingofcovid19vaccinefollowup AT mcgrathanikal unilateralaxillaryadenopathyinthesettingofcovid19vaccinefollowup AT drotmanmichele unilateralaxillaryadenopathyinthesettingofcovid19vaccinefollowup AT dodelzonkaterina unilateralaxillaryadenopathyinthesettingofcovid19vaccinefollowup |